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Abstract
Background: Currently, there is minimal data available highlighting the prevalence of venous thromboembolism in
patients infected with coronavirus disease 2019 (COVID-19). This case report with a literature review emphasizes a
unique presentation of COVID-19 that is highly important for health care providers to consider when treating their
patients.
Case report: A 65-year-old Caucasian male patient presented to the emergency department with a 2-day history of
dyspnea on exertion after his wife’s recent diagnosis of COVID-19. He additionally had experienced a couple of
episodes of self-resolving diarrhea a few days before presentation. Based on the patient’s clinical presentation and
the laboratory workup identifying an elevated D-dimer, a computed tomography angiogram of the chest was
obtained, which was significant for moderately large, bilateral pulmonary emboli with a saddle embolus, and an
associated small, left lower lobe, pulmonary infarct. Ultrasound of the lower extremity showed non-occlusive deep
vein thrombosis at the distal left femoral vein to the left popliteal vein. The patient was additionally diagnosed with
COVID-19 when the results of the COVID-19 polymerase chain reaction test returned as positive. The patient was
admitted to the COVID unit, and he was started on an intravenously administered, unfractionated heparin drip for
management of his bilateral pulmonary emboli and deep vein thrombosis. The patient’s clinical condition improved
significantly with anticoagulation, and he was observed in the hospital for 3 days, after which he was discharged
home on the enoxaparin bridge with warfarin. Post-discharge telephone calls at day 10 and week 4 revealed that
the patient was appropriately responding to anticoagulation treatment and had no recurrence of his symptoms
related to venous thromboembolism and COVID-19.
Conclusion: As COVID-19 continues to lead to significant mortality, more data is emerging that is exposing its
perplexing pathogenicity. Meanwhile, the presentation of venous thromboembolism in patients with COVID-19
remains an unusual finding. It is imperative for health care providers to be mindful of this unique association to
make necessary diagnostic evaluations and provide appropriate treatment for the patients.
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Introduction
The coronavirus disease 2019 (COVID-19) pandemic,
caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2), continues to desolate a
significant portion of the world’s population, and health
care providers continue to see new and frightening dis-
plays of its pathogenicity. We report an atypical case in-
volving a 65-year-old male patient with an acute saddle
pulmonary embolism and a deep vein thrombosis (DVT)
associated with COVID-19.
Case report
A 65-year-old Caucasian male patient presented to the
emergency room with a 2-day history of dyspnea on ex-
ertion. He also noted experiencing a couple of episodes
of diarrhea a few days before his dyspnea started, which
resolved on its own. The patient’s wife had recently been
diagnosed with COVID-19. The patient denied any fever,
cough, chest pain, or lower-extremity edema. His past
medical history included type 2 diabetes, hypertension,
and hyperlipidemia. His past surgical history included a
remote history of arthroscopic knee surgery. No per-
sonal history of malignancy was noted. No family history
of hypercoagulable disease or thromboembolism was
present. The patient had never smoked, denied drinking
alcohol, and had previously been taking metformin,
amlodipine, and simvastatin when at home.
His vital signs included blood pressure of 150/98
mmHg, pulse rate of 97 beats/min, respiratory rate of
18/min, oximetry 97% on room air, and a temperature
of 36.5 °C (97.8 °F). Pertinent findings on physical exam-
ination included clear breath sounds and a regular, rapid
heart rhythm on auscultation. There was no lower-
extremity edema or calf tenderness. An electrocardio-
gram (EKG) completed in the emergency room showed
sinus tachycardia at a rate of 113 bpm with no acute ST-
T segment changes. A chest x-ray showed no acute car-
diopulmonary findings. Laboratory data showed a white
count of 6.9 × 109/L, hemoglobin of 15.3 g/dL,
hematocrit at 44.9%, and platelet count of 158 × 109/L.
The basic metabolic panel was within the normal range
except for the blood sugar of 235 mg/dL. Troponin was
0.16 ng/mL, with normal total creatinine kinase. D-
dimer was elevated at 2241 ng/mL (Table 1). The routine
respiratory polymerase chain reaction (PCR) panel was
negative. A SARS-CoV-2 PCR test was sent from the
emergency room. A computed tomography (CT) angio-
gram of the chest showed moderately large, bilateral pul-
monary emboli with a saddle embolus and evidence of
slight right heart strain and pulmonary arterial hyperten-
sion with an associated small, left lower lobe, pulmonary
infarct (Figs. 1 and 2).
The patient was admitted to the COVID unit, and he
was started on an intravenously administered,
unfractionated heparin drip. Ultrasound of the lower ex-
tremity showed a non-occlusive DVT at the distal left
femoral vein to the left popliteal vein. Since the patient
was hemodynamically stable, tissue plasminogen activa-
tor (TPA) administration was not considered. His symp-
toms significantly improved with anticoagulation. The
hypercoagulable panel did not show any other active risk
factor for thrombotic conditions.
The patient was observed in the hospital for 3 days
and then was discharged home on the enoxaparin bridge
with warfarin. Since there was a high suspicion of SARS-
Table 1 Laboratory data
Laboratory test Results Reference range
White blood cell count 6.9 × 109/L 3.9–10.5 × 109/L
Red blood cell count 4.9 × 1012/L 4.33–5.73 × 1012/L
Hemoglobin 15.3 g/dL 13.6–17.0 g/dL
Hematocrit 44.9% 40.0–54.0%
Platelet count 158 × 109/L 150–450 × 109/L
Prothrombin 13.1 s 10.68–13.72 s
INR 1.1
D-dimer 2241 ng/mL 0–253.5 ng/mL
Sodium 138mmol/L 137–145mmol/L
Potassium 4.5 mmol/L 3.4–5.1 mmol/L
Chloride 103mmol/L 98–107mmol/L
Carbon dioxide 23 mmol/L 22–30mmol/L
Anion gap 12 6–22
Blood urea nitrogen 16 mg/dL 7–17 mg/dL
Creatinine 1.2 mg/dL 0.7–1.2 mg/dL
Glucose 235mg/dL 60–110mg/dL
Troponin I 0.16 ng/mL 0.00–0.10 ng/mL
Creatine kinase 71 U/L 55–170 U/L
INR international normalized ratio
Fig. 1 Computed tomography (CT) angiogram of the chest showing
large, bilateral pulmonary emboli with a saddle embolus (blue arrow)
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CoV-2 infection because of exposure through the family
member, the patient was instructed to follow strict
COVID isolation precautions. Eight days later, his
COVID-19 test also came back as positive. Post-
discharge telephone calls at day 10 and week 4 revealed
that the patient was appropriately responding to anticoa-
gulation treatment and had no recurrence of his symp-
toms related to VTE/COVID-19.
Discussion
The COVID-19 pandemic started in December 2019
with a collection of patients presenting with pneumonia
of unknown origin connected to a seafood wholesale
market in Wuhan, China [1]. The source of this presen-
tation was identified as a novel coronavirus, later named
as severe acute respiratory syndrome coronavirus-2
(SARS-CoV-2) and the disease it causes was named as
coronavirus disease 2019 (COVID-19) [1]. Coronaviruses
are a large group of enveloped ribonucleic acid (RNA)
viruses that are distributed among animals such as pigs,
bats, camels, and cats. When humans acquire these
viruses, they commonly cause mild-to-moderate upper-
respiratory diseases [2]. Three of these coronaviruses,
severe acute respiratory syndrome (SARS) coronavirus,
Middle East respiratory syndrome (MERS) coronavirus,
and SARS-CoV-2 have now been known to cause severe,
and often fatal disease in humans [2].
New evidence, although very limited at this point,
showing venous thromboembolism (VTE) as a complica-
tion of COVID-19, has started to emerge [3]. The exact
mechanism of thrombus formation can be variable, but
it is postulated that COVID-19 can lead to an increase
in the inflammatory response, hypoxia, immobilization,
and disseminated intravascular coagulation (DIC), all of
which can increase an individual’s propensity to arterial
and venous thromboembolic disease [3].
Viral infections, in general, can lead to an imbalance
between pro- and anticoagulant states during the course
of the disease and it often involves the disruption of the
vascular endothelium [4]. Various pathways involving
the coagulation cascade, including elevated von Willeb-
rand factor, cause the development of cross-linked fibrin
clots. The breakdown of these clots leads to elevation of
D-dimer levels and fibrin degradation product levels,
both of which are associated with poor prognosis in
COVID-19 patients, including the need for intensive
care unit (ICU) admission, and even death [5, 6]. This
activation of the systemic coagulation, along with immo-
bility associated with bed rest, in COVID-19 patients in-
creases the risk of VTE [3, 4, 6].
In a single-center cohort study, Middeldorp et al. re-
ported objectively confirmed VTE incidence rates of
16%, 33%, and 42% at days 7, 14, and 21, respectively,
among hospitalized patients with COVID-19, despite re-
ceiving thrombosis prophylaxis. This, however, was a
single-center cohort study with a small sample size of
199 patients [6]. In a separate study, Klok et al. reported
a 31% incidence of objectively confirmed VTE and arter-
ial thrombotic complications despite standard throm-
botic prophylaxis [3]. This again is a retrospective study
with a small sample size of 184 patients. In another
retrospective cohort study of 388 patients with COVID-
19, Lodigiani et al. reported a cumulative VTE incidence
rate of 21%, with half of those events occurring within
24 h of admission to the hospital [7].
Due to the lack of availability of sufficient data, the
concept of whether or not to use prophylactic anticoagu-
lation in hospitalized COVID-19 patients to improve
their overall clinical outcome continues to remain con-
troversial [4]. Klok et al. and Middeldorp et al. advise
against prophylactically initiating treatment-dose antic-
oagulation in all hospitalized patients with COVID-19
and instead are recommending physicians to use a lower
threshold for appropriate diagnostic tests for evaluation
of thrombotic complications including DVT and pul-
monary embolism [3, 6]. More research involving ran-
domized, controlled clinical trials are needed to know
definitely whether preemptive and prolonged treatment-
dose anticoagulation leads to a favorable clinical out-
come in patients with COVID-19 infection.
Conclusion
COVID-19 continues to cause significant mortality as
more data is emerging that is aiding in piecing together
its perplexing pathogenicity. Scant emerging data is
suggesting COVID-19’s role in increased activation of
systemic coagulation and further leading to thrombo-
embolic complications such as pulmonary embolism.
Fig. 2 Computed tomography (CT) angiogram of the chest (lung
window) showing an evolving small, left lower lobe, pulmonary
infarct (green arrow)
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Here, we presented a case highlighting this very rare
presentation. For future direction, we recommend
more research focusing on ethical, sound, randomized,
controlled clinical trials evaluating the efficacy, safety,
dosing, and duration of prophylactic anticoagulation
in all hospitalized patients infected with COVID-19 in
order to improve survival rates.
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